Compare BETR & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BETR | FULC |
|---|---|---|
| Founded | 2014 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 518.9M | 467.8M |
| IPO Year | N/A | 2019 |
| Metric | BETR | FULC |
|---|---|---|
| Price | $21.81 | $3.72 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 8 |
| Target Price | ★ $40.00 | $16.38 |
| AVG Volume (30 Days) | 272.0K | ★ 1.9M |
| Earning Date | 05-07-2026 | 04-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $55.02 | N/A |
| Revenue Next Year | $65.66 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.57 | $2.83 |
| 52 Week High | $94.06 | $15.74 |
| Indicator | BETR | FULC |
|---|---|---|
| Relative Strength Index (RSI) | 38.39 | 44.94 |
| Support Level | N/A | $3.41 |
| Resistance Level | $33.00 | $4.02 |
| Average True Range (ATR) | 1.88 | 0.18 |
| MACD | -0.25 | 0.09 |
| Stochastic Oscillator | 14.03 | 67.71 |
Better Home & Finance Holding Co is a technology-enabled homeownership company that provides mortgage, home equity, and related services through a digital platform. The company operates through two reportable segments: Home Finance, which focuses on residential mortgage origination, including purchase, refinance, and home equity products, generating revenue mainly from loan sales; and Banking, which, through its U.K. subsidiary Birmingham Bank, offers a range of financial products and services to consumers and small businesses. It generates the majority of its revenue from the Home Finance segment.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.